Author/Editor     Vene, Nina
Title     Antikoagulacijsko zdravljenje pri bolnikih z atrijsko fibrilacijo
Translated title     Anticoagulant treatment in atrial fibrillation
Type     članek
Source     In: Kenda MF, Rakovec P, editors. Sodobna obravnava motenj srčnega ritma. 9. kardiološki dnevi; 2000 okt 20-21; Šmarješke toplice. Ljubljana: Združenje kardiologov Slovenije,
Publication year     2000
Volume     str. 157-63
Language     slo
Abstract     Atrial fibrillation is a major independent risk factor for stroke. The overall risk of stroke in non-valvular atrial fibrillation patients averages about 5 %/y, but with wide variation depending on the presence of coexistent risk factors. Advancing age, prior stroke or transient cerebral ischaemia, hypertension, and impaired function of the left ventricle are known risk factors. Stratification of stroke risk identifies non-valvular atrial fibrillation patients who benefit most or least from anticoagulation. Warfarin (target INR 2,5; range 2,0-3,0) is recommended for high risk patients, whereas aspirin is indicated to those with a low stroke risk. In patients considered to have a moderate risk of stroke, bleeding risk and patient's preference should influence the choice of antithrombotic treatment. Based on a very high risk of thromboembolism, anticoagulant treatment is strongly recommeded in patients with rhematic mural valve disease and atrial fibrillation. Anticoagulation is indicated 3 weeks prior to cardioversion and 4 weeks after it to patients with atrial fibrillation or flutter lasting more than 48 hours who are considered for cardioversion.
Descriptors     ATRIAL FIBRILLATION
ANTICOAGULANTS
ELECTRIC COUNTERSHOCK
CEREBRAL EMBOLISM AND THROMBOSIS